<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137458</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0227</org_study_id>
    <secondary_id>2019-A01277-50</secondary_id>
    <nct_id>NCT04137458</nct_id>
  </id_info>
  <brief_title>Exploration of the Relationship Between Inflammation and Integrity of the Blood-Brain Barrier in Suicidal Behaviour</brief_title>
  <acronym>IBIS</acronym>
  <official_title>Exploration of the the Relationship Between Inflammation and Integrity of the Blood-brain Barrier in Suicidal Behaviour</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have revealed an association between history of suicide attempt and&#xD;
      inflammatory markers in both the cerebrospinal fluid and the plasma. Post mortem studies have&#xD;
      shown an increase in microglial activation in the brain tissue of suicide victims. However&#xD;
      the relationship between peripheral and central inflammation in suicide is probably mediated&#xD;
      by complex biological processes that are yet elucidated. An increase of blood S100B levels&#xD;
      (biomarker of neurovascular damage; PMID 14530574) has been reported in adolescents with&#xD;
      suicidal ideation vs. controls and independently of psychiatric disorder. The investigators&#xD;
      hypothesize that peripheral inflammation may alter BBB which normally acts as a filter to&#xD;
      ensure proper neuronal functioning in suicidal vs. non suicidal patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      105 participants will be recruited :&#xD;
&#xD;
        -  35 depressed patients having attempted suicide (maximum 3 attempts in life)&#xD;
&#xD;
        -  35 depressed patients without history of suicide attempt (affective controls)&#xD;
&#xD;
        -  35 healhy controls with no lifetime psychiatric history.&#xD;
&#xD;
      Only one visit is planned. A clinical assessment (2 hours) will be performed to characterise&#xD;
      pschopathology and suicidal characteristics. Blood and salivary samples will be obtained in&#xD;
      order to measure inflammatory markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood level of S100B</measure>
    <time_frame>at inclusion</time_frame>
    <description>Blood level of S100B measured in 3 groups (i.e. suicide attempters, affective controls, healthy controls)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of leukocyte signature associated with suicidal behavior and depression</measure>
    <time_frame>at inclusion</time_frame>
    <description>Comparison of the number and percentage of leukocytes (lymphocytes, monocytes, neutrophils) in the blood between the 3 patients groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of peripheral inflammation of each group</measure>
    <time_frame>at inclusion</time_frame>
    <description>Characterization of activation state of leukocytes of CD4 / CD8 (T cells), NK cells, CD14 / CD33 (monocytes / macrophages)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of general peripheral inflammation</measure>
    <time_frame>at inclusion</time_frame>
    <description>Between groups comparison of blood levels of CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pro-inflammatory profile based on cytokins of each group</measure>
    <time_frame>at inclusion</time_frame>
    <description>Serum pro-inflammatory interleukins (IL) -1b, IL2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12, IL-13 , TGF-b, interferon IFN-g, TNF-a, TNF-b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of salivary interleukins</measure>
    <time_frame>at inclusion</time_frame>
    <description>Profile of salivary interleukins Il-6, Il-13 et Il-17 within and between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of glial fibrillary actin protein (GFAP)</measure>
    <time_frame>at inclusion</time_frame>
    <description>Between group comparison of serum levels (ng / ml) of glial fibrillary actin protein (GFAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of specific neuronal enolase (NSE)</measure>
    <time_frame>at inclusion</time_frame>
    <description>Between group comparison of serum levels (ng / ml) of specific neuronal enolase (NSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of ubiquitinar-carboxy-terminal hydrolase L1 (UCH-L1)</measure>
    <time_frame>at inclusion</time_frame>
    <description>Between group comparison of serum levels (ng / ml) of ubiquitinar-carboxy-terminal hydrolase L1 (UCH-L1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary levels of S100B protein</measure>
    <time_frame>at inclusion</time_frame>
    <description>Between group comparison of salivary levels of S100B protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary levels of specific neuronal enolase (NSE)</measure>
    <time_frame>at inclusion</time_frame>
    <description>Between group comparison of salivary levels of specific neuronal enolase (NSE) in the 3 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary levels of GFAP</measure>
    <time_frame>at inclusion</time_frame>
    <description>Between group comparison of salivary levels of GFAP in the 3 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vitro fluorescence ratio Dapi / phalloidin</measure>
    <time_frame>at inclusion</time_frame>
    <description>The fluorescence ratio Dapi / phalloidin in a culture of neurovascular cells in the presence of the serum of the subjects (in vitro) in the 3 groups</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigator will withdraw biological samples and a biological and DNA bank will also be realized</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological analysis</intervention_name>
    <description>Blood and salivary samples will be taken at inclusion and a psychiatric assessment will be carried out</description>
    <arm_group_label>Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-55 years old&#xD;
&#xD;
          -  Able to understand nature, aims, and methodology of the study&#xD;
&#xD;
        Depending on the population :&#xD;
&#xD;
          -  Current depressive episode (according to DSM-5 criteria) with a recent suicide attempt&#xD;
             (within the 8 days before inclusion) and no more than 3 attempts in life&#xD;
&#xD;
          -  Current depressive episode (according to DSM-5 criteria) without suicide attempt&#xD;
&#xD;
          -  No psychiatric history (according to DSM-5 criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory diseases or intercurrent infections, or chronic diseases such as&#xD;
             hepatitis C or B, HIV, Alzheimer's, cancer or autoimmune disease&#xD;
&#xD;
          -  Current antibiotic or anti-inflammatory treatments&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Lifetime Schizoaffective disorder or schizophrenia&#xD;
&#xD;
          -  On protective measures (guardianship or trusteeship)&#xD;
&#xD;
          -  Deprived of liberty subject (administrative decision)&#xD;
&#xD;
          -  In exclusion period for another protocol&#xD;
&#xD;
          -  Not affiliated to a social security agency&#xD;
&#xD;
          -  Unable to understand and/or answer a questionnaire&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Courtet, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Courtet, MD PhD</last_name>
    <phone>+33 4 67 33 85 81</phone>
    <email>p-courtet@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie Olie, MD PhD</last_name>
    <phone>+33 4 67 33 85 81</phone>
    <email>e-olie@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Genty, MD</last_name>
      <phone>+33 4 67 99 61 45 75</phone>
      <email>c-genty@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psychiatry</keyword>
  <keyword>Blood Brain Barrie</keyword>
  <keyword>Suicide attempt</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

